ClinicalTrials.gg
CompletedNCT01765543Updated Dec 15, 2016Results posted

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

A Phase 1 interventional study of Rifampin and Vemurafenib in Malignant Melanoma, Neoplasms, sponsored by Hoffmann-La Roche. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-15.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies testing vemurafenib in Melanoma — 2 open to participants now, 2 under way, 1 of them phase 3. Vemurafenib · Melanoma.

Enrollment
23rd of 56
27 · median 18
Started
2013
with 17 others
Phase 1
26 of 56
none open now
Registered
26th of 56
by date
Lead sponsor
23 of 56
Hoffmann-La Roche

Among the 56 studies testing vemurafenib in Melanoma, this one is the 23rd largest by enrollment, is one of 18 that started in 2013, is one of 26 in phase 1, and was the 26th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 56 studies testing vemurafenib in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vemurafenib

Vemurafenib: first FDA approval 2011 (ZELBORAF), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing vemurafenib in Melanoma, or all of them as a file.
02

Study summary

This open-label, multi-center, three-period, one-sequence study will investigate the effect of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF without acceptable standard treatment options. Eligible participants will have the option to continue treatment with vemurafenib as part of an extension study GO28399 (NCT01739764).

03

Conditions studied

  • Malignant Melanoma, Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with either unresectable Stage IIIc or Stage IV melanoma positive for the BRAF V600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a Deoxyribonucleic acid (DNA) sequencing method, and who have no acceptable standard treatment options
  • (ECOG) performance status 0 to 2
  • of greater than or equal to (>/=) 12 weeks
  • Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
  • Adequate hematologic and end organ function
  • Female participants of and male participants with partners of childbearing potential must agree to always use 2 effective methods of
  • Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose of study drug
  • Requirement for immediate or urgent treatment with daily vemurafenib and for whom the intermittent schedule of vemurafenib employed during the 24-day period for this trial is not clinically acceptable
  • Allergy or to components of the vemurafenib formulation
  • Experimental therapy within 4 weeks prior to first dose of study drug
  • Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug, or anticipation of the need for major surgery during study treatment
  • Prior anti-cancer therapy within 28 days before the first dose of study drug
  • History of cardiac or pulmonary dysfunction
  • History of symptomatic congestive heart failure of any class or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction within 6 months prior to first dose of study drug
  • Current dyspnea at rest, owing to complications of advanced or any requirement for supplemental oxygen to perform activities of daily living
  • History of congenital long syndrome or corrected QT interval (QTc) greater than (>) 450 milliseconds
  • Active central nervous system lesions
  • Uncontrolled or poorly controlled diabetes
  • Current severe, uncontrolled systemic disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Vemurafenib + Rifampin

    There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).

    Drug: Rifampin · Drug: Vemurafenib

Interventions

  • Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).

  • Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).

    Also known as: RO5185426, Zelboraf

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib

    AUClast is the area under the vemurafenib plasma concentration versus time curve from time zero to the time of last measured concentration of vemurafenib (Tlast). Area under the curve (AUC) is a measure of the plasma concentration of a drug over time. AUClast is presented in micrograms times (\*) hour per milliliter (mcg\*h/mL).

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  2. Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib

    AUC(0-inf) is the AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). AUC is a measure of the plasma concentration of a drug over time. AUC(0-inf) is presented in mcg\*h/mL.

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  3. Maximum Observed Plasma Concentration (Cmax) of Vemurafenib

    Cmax is the maximum observed plasma vemurafenib concentration, presented in microgram per milliliter (mcg/mL).

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

Other outcomes

  1. Time to Reach Cmax (Tmax) of Vemurafenib

    Tmax is the time from vemurafenib administration to reach Cmax for vemurafenib.

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  2. Plasma Elimination Half Life (t1/2) of Vemurafenib

    Plasma elimination half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  3. Plasma Apparent Clearance (CL/F) of Vemurafenib

    Clearance of a drug is a measure of the rate at which a drug is removed (metabolized or eliminated by normal biological processes) from the blood. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  4. Area Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib

    AUC(0-168) is the AUC from time zero (pre-dose) to 168 hours (time point for last blood sample collection). AUC is a measure of the plasma concentration of a drug over time. AUC(0-168) is presented in mcg\*h/mL.

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

  5. Percent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib

    The AUCpeo, that is, percent area obtained after extrapolation from Tlast to infinity is calculated by using the formula AUCpeo = 100\*(AUC\[0-inf\] minus AUC\[0-last\])/AUC(0-inf). This parameter provides information about what percentage of the theoretical curve AUC(0-inf) is possible to determine experimentally (AUC0-last).

    Time frame: Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)

07

Results

Posted Dec 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneVemurafenib + Rifampin (All Periods)
Started27
Completed24
Not completed3
Withdrew: Death1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryArea Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib

AUClast is the area under the vemurafenib plasma concentration versus time curve from time zero to the time of last measured concentration of vemurafenib (Tlast). Area under the curve (AUC) is a measure of the plasma concentration of a drug over time. AUClast is presented in micrograms times (\*) hour per milliliter (mcg\*h/mL).

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · mcg*h/mL
Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib
mcg*h/mLVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib125 ± 101.476.7 ± 75.3
Statistical analysis
  • Vemurafenib (Intervention Period A) vs Vemurafenib + Rifampin (Intervention Period C) · Geometric mean ratio: 0.614 · 90% CI 0.484 to 0.780
PrimaryArea Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib

AUC(0-inf) is the AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). AUC is a measure of the plasma concentration of a drug over time. AUC(0-inf) is presented in mcg\*h/mL.

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · mcg*h/mL
Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib
mcg*h/mLVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib131 ± 104.278.1 ± 74.3
Statistical analysis
  • Vemurafenib (Intervention Period A) vs Vemurafenib + Rifampin (Intervention Period C) · Geometric mean ratio: 0.596 · 90% CI 0.469 to 0.759
PrimaryMaximum Observed Plasma Concentration (Cmax) of Vemurafenib

Cmax is the maximum observed plasma vemurafenib concentration, presented in microgram per milliliter (mcg/mL).

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · mcg/mL
Maximum Observed Plasma Concentration (Cmax) of Vemurafenib
mcg/mLVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Maximum Observed Plasma Concentration (Cmax) of Vemurafenib4.45 ± 63.34.95 ± 59.1
Statistical analysis
  • Vemurafenib (Intervention Period A) vs Vemurafenib + Rifampin (Intervention Period C) · Geometric mean ratio: 1.11 · 90% CI 0.908 to 1.36
Other pre-specifiedTime to Reach Cmax (Tmax) of Vemurafenib

Tmax is the time from vemurafenib administration to reach Cmax for vemurafenib.

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Median · hours
Time to Reach Cmax (Tmax) of Vemurafenib
hoursVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Time to Reach Cmax (Tmax) of Vemurafenib4.00 (1.98 to 7.92)4.00 (1.98 to 6.02)
Other pre-specifiedPlasma Elimination Half Life (t1/2) of Vemurafenib

Plasma elimination half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Mean · hours
Plasma Elimination Half Life (t1/2) of Vemurafenib
hoursVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Plasma Elimination Half Life (t1/2) of Vemurafenib29.7 ± 17.611.6 ± 5.24
Other pre-specifiedPlasma Apparent Clearance (CL/F) of Vemurafenib

Clearance of a drug is a measure of the rate at which a drug is removed (metabolized or eliminated by normal biological processes) from the blood. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · liters/hour
Plasma Apparent Clearance (CL/F) of Vemurafenib
liters/hourVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Plasma Apparent Clearance (CL/F) of Vemurafenib7.35 ± 104.212.3 ± 74.3
Other pre-specifiedArea Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib

AUC(0-168) is the AUC from time zero (pre-dose) to 168 hours (time point for last blood sample collection). AUC is a measure of the plasma concentration of a drug over time. AUC(0-168) is presented in mcg\*h/mL.

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · mcg*h/mL
Area Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib
mcg*h/mLVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Area Under the Plasma Concentration Time-curve From Zero to 168 Hours [AUC(0-168)] of Vemurafenib126 ± 99.678.0 ± 74.2
Other pre-specifiedPercent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib

The AUCpeo, that is, percent area obtained after extrapolation from Tlast to infinity is calculated by using the formula AUCpeo = 100\*(AUC\[0-inf\] minus AUC\[0-last\])/AUC(0-inf). This parameter provides information about what percentage of the theoretical curve AUC(0-inf) is possible to determine experimentally (AUC0-last).

Time frame:
Predose (0 hour), 1, 2, 4, 6, 8, 12, 24, 30-32, 48, 72, 96, 120, 168 hours post vemurafenib-dose on Day 1 (Period A) and Day 17 (Period C)
Reported as:
Geometric mean · percent AUC
Percent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib
percent AUCVemurafenib (Intervention Period A)Vemurafenib + Rifampin (Intervention Period C)
Percent Extrapolated AUC(0-inf) (AUCpeo) of Vemurafenib2.75 ± 150.41.26 ± 95.9

Adverse events

Collected over Day 1 up to 28 days after last dose of study drug (up to 51 days overall). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vemurafenib (Intervention Period A)—0/27 (0%)4/27 (14.8%)
Rifampin (Intervention Period B)—0/26 (0%)8/26 (30.8%)
Vemurafenib + Rifampin (Intervention Period C)—2/25 (8%)5/25 (20%)
Vemurafenib + Rifampin (All Periods)—2/27 (7.4%)12/27 (44.4%)
Most frequent serious events
Most frequent serious events
EventVemurafenib (Intervention Period A)Rifampin (Intervention Period B)Vemurafenib + Rifampin (Intervention Period C)Vemurafenib + Rifampin (All Periods)
Cardiac arrestCardiac disorders0/270/261/251/27
Confusional statePsychiatric disorders0/270/261/251/27
Most frequent other events
Most frequent other events
EventVemurafenib (Intervention Period A)Rifampin (Intervention Period B)Vemurafenib + Rifampin (Intervention Period C)Vemurafenib + Rifampin (All Periods)
ChromaturiaRenal and urinary disorders0/275/260/255/27
HeadacheNervous system disorders2/272/263/254/27
ArthralgiaMusculoskeletal and connective tissue disorders1/272/260/253/27
NauseaGastrointestinal disorders0/270/262/252/27
ConstipationGastrointestinal disorders0/272/260/252/27
DiarrhoeaGastrointestinal disorders1/270/261/252/27
Decreased appetiteMetabolism and nutrition disorders0/271/261/252/27
Pain in extremityMusculoskeletal and connective tissue disorders1/270/261/252/27

Baseline characteristics

The intent-to-treat (ITT) population included all participants who were enrolled in the study.

Age, Continuous
Age, Continuous(years)Vemurafenib + Rifampin (All Periods)
Mean57.9 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Vemurafenib + Rifampin (All Periods)
Female9
Male18
08

Study locations

15 sites
  • Rogers, Arkansas 72758, United States
  • Pleasant Hill, California 94523, United States
  • Middletown, Ohio 45042, United States
  • Dallas, Texas 75246, United States
  • Porto Alegre, RS 90020-090, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Porto Alegre, RS 90840-440, Brazil
  • Varazdin, 42000, Croatia
  • Zagreb, 10000, Croatia
  • Alexandria, 21131, Egypt
  • Cairo, 11796, Egypt
  • Dakahlia, 324, Egypt
  • Tanta, Egypt
  • Cape Town, 7570, South Africa
  • Port Elizabeth, 6045, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2013
First posted
Jan 10, 2013
Start
Jul 2013
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Dec 15, 2016
Last update
Dec 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01765543
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Jul 2013
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Dec 15, 2016
Last update
Dec 15, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rifampin · Vemurafenib

Start the discussion